St. Louis, MO
Home ► Blog ► U.S. Food & Drug Administration Warns About Multaq Safety
Multaq, a drug used successfully to reduce the risk of death, stroke, and hospitalization for patients with occasional atrial fibrillation have been found to double the risk of death for those with a permanent form of the erratic rhythm. Sanofi’s Multaq is approved for the treatment of patients whose hearts intermittently race with quick and inefficient contractions or who suffer from atrial fibrillation that lasts less than six months.
Multaq was first approved for use in the United States by the FDA in July of 2009 and was indicated for the treatment of atrial fibrillation or atrial flutter in certain patients. Based on safety signals related to liver injury received by the FDA in late 2010, the agency required a Multaq label to change in February 2011. The updated label notes that the use of Multaq should be stopped if liver injury is suspected.
After the drug was approved, analysts estimated that Sanofi-Aventis would earn $1.35 billion in annual sales by 2014. This, in fact, did not happen due to the long list of adverse side effects reported.
In an effort to boost Multaq’s prospects after a decline in sales, Sanofi began a trial aiming to show that the drug can stave off cardiovascular episodes, such as stroke and heart attack, in patients with permanent atrial fibrillation. Sanofi had hoped that a study of 3,236 patients would prove that Multaq would also have success in patients with a more serious form of the condition.
The study was designed to evaluate the effectiveness of Multaq in patients suffering from a permanent form of atrial fibrillation. Among patients receiving Multaq, there were 21 deaths from cardiovascular causes. In the placebo group, there were ten such deaths. The study had to be halted after a monitoring committee found that people taking the drug experienced two-fold increases in death, stroke, and heart failure.
According to the European Medicines Agency (EMA), Multaq should only be prescribed after alternative treatment options. In response to the EMA’s warning, the FDA began conducting its own separate review of the prescription drug.
In January 2011, the FDA issued a warning to patients with atrial fibrillation (abnormal heart rhythms) that Multaq showed twice as many deaths as compared to those who did not take the drug. This warning came as a result of a 3,000-patient trial that Sanofi-Aventis halted after they noticed an increased risk of cardiovascular events among patients with permanent atrial fibrillation
In a similar warning on September 23, 2011, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CMHP) recommended that use of Multaq be restricted. The CMHP began evaluating data as a result of post-marketing reports of severe liver injuries among users of Multaq. The CMHP also reviewed potential cardiovascular injuries following the early termination of a clinical trial of Multaq in an off-label population.
Ultimately, the CMHP determined that use of Multaq as approved increased the user’s risk of injury to the liver and the lungs. As a result of the increased risk of liver and lung injury, the CMHP has recommended that Multaq is used only after other treatment options have been considered, and only in patients in whom atrial fibrillation is no longer present.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
« Read more related news
Contact us by phone at 1-888-508-6752 or email us below.
© 2019 TorHoerman Law LLC.
The contents of this webpage have been prepared by TorHoerman Law, LLC for informational purposes only. None of this information is intended as either legal or medical advice or opinions. No attorney/client relationship is established with use of this website. Sending or receiving information through this site, posting to our blogs/news site does not establish an attorney/client relationship. An attorney/client relationship with TorHoerman Law is established only by an express and written agreement by TorHoerman Law to represent you. Our attorneys make a case-by-case assessment of any claims and results may vary depending on the facts concerning any case. The attorneys at TorHoerman Law are licensed to practice in Illinois, Missouri, and California. In some circumstances, cases may be sent to other qualified lawyers. In those circumstances, TorHoerman Law maintains joint responsibility.